Today: 19 May 2026
Australia stock market jumps as miners rally, tech gets slammed; Xero sinks

Australia stock market jumps as miners rally, tech gets slammed; Xero sinks

Sydney, Feb 4, 2026, 21:49 AEDT — Market closed

  • Australia’s S&P/ASX 200 rose 0.8%, driven by strength in materials and energy sectors
  • Technology shares plunged, led by Xero, which dropped over 15% in a single session
  • Traders digested the RBA’s rate hike alongside another global selloff in software stocks

Australian shares ended Wednesday on a strong note, propelled by gains in miners and banks despite a sharp drop in tech stocks. The S&P/ASX 200 climbed 0.8% to 8,927. Materials surged 3.6% and energy rose 3.0%, while information technology plunged 9.4%. Yancoal Australia led the charge, jumping 9%, but Xero tumbled 15.9% and WiseTech Global dropped 10.7%.

The split tape followed the Reserve Bank of Australia’s 25 basis-point increase — raising the cash rate to 3.85%, its first rise in two years. Governor Michele Bullock said she wasn’t sure if this marked the start of a tightening cycle and that the board would be “actively monitoring” incoming data. Reuters

Beyond Australia, software and data stocks have been hit hard as investors react to Anthropic’s latest plug-ins for its Claude Cowork agent, raising fresh concerns over AI’s disruptive impact. IG chief markets strategist Chris Beauchamp described Anthropic as “parking its tanks on their lawn,” highlighting growing doubts about the resilience of certain business models. Reuters

On the ASX 200, miners and coal stocks took the lead. Yancoal jumped 8.8% to A$6.29, South32 climbed 6.3% to A$4.80, and Regis Resources rose 6.1% to A$8.18. On the downside, Xero plunged 15.7% to A$81.06, WiseTech Global slid 10.3% to A$51.49, and Technology One lost 10.5%, closing at A$22.65.

Tech stocks took a big hit early on. The ASX 200 Tech Index plunged as much as 8%, with Xero and WiseTech dropping anywhere from high single digits to double digits. Technology One wasn’t far behind, slipping nearly 10%. Gold miners saw gains after gold bounced back, and MarketIndex reported JPMorgan upgraded Northern Star Resources to “Buy” ahead of its half-year results on Feb. 12. Neuren Pharmaceuticals went into a trading halt, expected to last until Feb. 6 at the latest. Market Index

The market ended the session appearing stronger than the mood suggested. Advancers weren’t overwhelming, and the index’s rise depended heavily on a few resource giants, while tech and other growth sectors slipped.

Rate-sensitive sectors remained shaky as investors adjusted to the prospect of higher borrowing costs. While a stronger rate environment can boost banks’ margins, it also casts doubt on credit growth and household spending with mortgage rates on the rise.

Commodities are steering the market once more, and Australia feels the impact both ways. When metals and energy prices rebound, miners and producers get a boost. But a firmer Australian dollar eats into exporters’ offshore earnings once those profits are converted back into local currency.

The rebound isn’t straightforward. Should the global software selloff continue or spread to broader risk assets, local tech could weigh heavily on sentiment. Plus, any dip in commodity prices would leave the index more vulnerable than it appears.

Traders in the next session will watch offshore tech and AI news closely, while also tracking the rate direction following the RBA’s pivot. Several company-specific catalysts are lined up over the coming days, prompting investors to brace for sudden moves around those announcements.

Stock Market Today

  • Hot Inflation Creates New Stock Winners and Losers
    May 19, 2026, 5:41 AM EDT. Hot inflation is reshaping the stock market landscape, creating a distinct group of winners and losers. Rising prices affect sectors unevenly, with companies able to pass on costs to consumers gaining an edge, while others face squeezed margins. Investors are adjusting portfolios, favoring industries such as energy and consumer staples that typically perform well during inflationary periods. Conversely, sectors like technology and discretionary retail are encountering headwinds due to increased input costs and reduced consumer spending power. This evolving dynamic highlights the importance of sector selection amid persistent inflationary pressures.

Latest articles

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

19 May 2026
Alphabet shares rose in pre-market trading Tuesday after Google and Blackstone announced a U.S. AI cloud venture, with Blackstone committing $5 billion to add 500 megawatts of data-center capacity by 2027. Alphabet’s Class A shares closed Monday at $396.94 and were quoted at $401.09 before the market opened. The move coincides with the first day of Google I/O and follows strong Q1 earnings.
GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight

GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight

19 May 2026
GeoVax Labs shares surged nearly 80% to $2.21 Monday after announcing a $3 million private placement amid heightened interest in biodefense following a WHO emergency alert over Ebola in Africa. The company does not sell an approved Ebola vaccine; its lead candidate targets mpox and smallpox. GeoVax reported $1.3 million in cash at March 31 and a quarterly net loss of $5.3 million. The new funding is expected to close around May 19.
Evolution stock jumps on €2 billion move

Evolution stock jumps on €2 billion move

19 May 2026
Evolution AB shares surged 9% in Stockholm after the company announced a €2 billion share buyback, one of Sweden’s largest. The buyback starts immediately and may run until the 2027 annual meeting, capped at 10% of shares. The OMXS30 index rose just 0.75% in comparison. Evolution also secured a €300 million revolving credit facility from J.P. Morgan SE and Citibank Europe.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Adobe stock slips again: ADBE hit by Piper Sandler downgrade as AI disruption fears linger
Previous Story

Adobe stock slips again: ADBE hit by Piper Sandler downgrade as AI disruption fears linger

Intel stock slides after CEO flags new GPU push; investors eye Nvidia’s next readout
Next Story

Intel stock slides after CEO flags new GPU push; investors eye Nvidia’s next readout

Go toTop